Seaport Therapeutics Appoints Dr. Sharon Mates to Board of Directors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy BNTC?
Source: Newsfilter
- New Board Member: Seaport Therapeutics has appointed Dr. Sharon Mates to its Board of Directors; she previously co-founded and served as CEO of Intra-Cellular Therapies, leading the company to a $14.6 billion acquisition by Johnson & Johnson in 2025, showcasing her exceptional leadership in the biopharmaceutical sector.
- Extensive Industry Experience: Dr. Mates brings decades of experience in neuropsychiatry, having successfully commercialized CAPLYTA® and continued its market growth post-acquisition by J&J, which is expected to significantly support Seaport's mission.
- Strategic Collaboration Outlook: Dr. Mates expressed great interest in Seaport's programs and looks forward to collaborating closely with founder Daphne Zohar and other team members to drive the company's continued growth and develop life-changing treatments for patients.
- Innovative Drug Development: Seaport Therapeutics focuses on developing new medicines for depression, anxiety, and other neuropsychiatric disorders, and Dr. Mates' addition is anticipated to enhance the company's R&D capabilities, helping it stand out in a competitive market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BNTC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BNTC
Wall Street analysts forecast BNTC stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.050
Low
32.00
Averages
32.00
High
32.00
Current: 12.050
Low
32.00
Averages
32.00
High
32.00
About BNTC
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Seaport Therapeutics Appoints Dr. Sharon Mates to Board of Directors
- New Board Member: Seaport Therapeutics has appointed Dr. Sharon Mates to its Board of Directors; she previously co-founded and served as CEO of Intra-Cellular Therapies, leading the company to a $14.6 billion acquisition by Johnson & Johnson in 2025, showcasing her exceptional leadership in the biopharmaceutical sector.
- Extensive Industry Experience: Dr. Mates brings decades of experience in neuropsychiatry, having successfully commercialized CAPLYTA® and continued its market growth post-acquisition by J&J, which is expected to significantly support Seaport's mission.
- Strategic Collaboration Outlook: Dr. Mates expressed great interest in Seaport's programs and looks forward to collaborating closely with founder Daphne Zohar and other team members to drive the company's continued growth and develop life-changing treatments for patients.
- Innovative Drug Development: Seaport Therapeutics focuses on developing new medicines for depression, anxiety, and other neuropsychiatric disorders, and Dr. Mates' addition is anticipated to enhance the company's R&D capabilities, helping it stand out in a competitive market.
See More
Benitec Biopharma Showcases BB-301 Clinical Results at MDA Conference
- Clinical Research Progress: Benitec showcased key clinical results for BB-301 at the 2026 MDA Conference, demonstrating significant and durable improvements in swallowing function and dysphagia symptom burden, potentially transforming the treatment landscape for OPMD patients.
- Patient Impact: With approximately 97% of OPMD patients suffering from severe dysphagia, BB-301's treatment could significantly enhance patients' quality of life by replacing the mutated PABPN1 gene with a functional protein, thereby reducing the risk of complications.
- Industry Forum Event: The Industry Forum Breakfast is scheduled for March 10, 2026, where Benitec's CEO Jerel A. Banks will present detailed clinical data on BB-301, attracting numerous industry experts and further enhancing the company's influence in the biotechnology sector.
- Regulatory Recognition: BB-301 has received Orphan Drug Designation from the EMA and both Orphan Drug and Fast Track Designations from the FDA, indicating its potential in treating rare diseases and possibly bringing future market opportunities and investor confidence to Benitec.
See More
Benitec Reports Q2 Earnings Miss with Strategic Upgrade
- Earnings Report Disappointment: Benitec's Q2 GAAP EPS of -$0.26 missed expectations by $0.03, resulting in a net loss of $11.8 million, indicating ongoing financial strain on the company.
- Market Reaction: Despite the earnings miss, early data from Benitec's BB-301 project and a cash infusion provide support for its future development, leading to a bullish outlook from the market.
- Rating Adjustment: Seeking Alpha's Quant Rating has classified Benitec's stock as bullish, reflecting analysts' confidence in its potential growth despite current financial challenges.
- Historical Financial Data: Historical financial data for Benitec shows that, despite facing challenges, the company is striving to improve its operational efficiency and market positioning to better compete in the future.
See More
Significant Progress in BB-301 Clinical Trials
- Responder Analysis: All four patients in Cohort 1 of the BB-301 study were formal responders at the 12-month follow-up, demonstrating durable responses to treatment, indicating the therapy's effectiveness in addressing Oculopharyngeal Muscular Dystrophy-related dysphagia.
- Long-term Efficacy Observation: Patient 1 showed continued disease-modifying effects at the 24-month follow-up, with significant improvements in post-swallow residue and total dysphagic symptom burden, suggesting BB-301 may provide long-term therapeutic benefits.
- FDA Meeting Scheduled: The company plans to engage with the FDA in mid-2026 to formalize the pivotal study design for BB-301, which will lay the groundwork for the successful progression of subsequent clinical trials.
- Financial Status Update: As of December 31, 2025, the company reported $189 million in cash and cash equivalents, and despite an operating loss of $13.8 million, R&D expenses remained consistent with the previous year, reflecting the company's commitment to advancing clinical development.
See More
Benitec Biopharma Announces Financial Results for Q2 2026 and Offers Operational Update
Financial Results: Benitec Biopharma has released its financial results for the second quarter of 2026, detailing its performance and financial health during this period.
Operational Update: The company has provided an operational update, highlighting key developments and progress in its ongoing projects and initiatives.
See More
Benitec Biopharma Reports Q2 EPS of USD -0.26
Company Overview: Benitec Biopharma is a biotechnology company focused on developing innovative therapies using its proprietary gene-silencing technology.
Financial Performance: The company reported a Q2 EPS of USD -0.26, indicating a loss per share for the quarter.
See More
Seaport Therapeutics Appoints Dr. Sharon Mates to Board of Directors
- New Board Member: Seaport Therapeutics has appointed Dr. Sharon Mates to its Board of Directors; she previously co-founded and served as CEO of Intra-Cellular Therapies, leading the company to a $14.6 billion acquisition by Johnson & Johnson in 2025, showcasing her exceptional leadership in the biopharmaceutical sector.
- Extensive Industry Experience: Dr. Mates brings decades of experience in neuropsychiatry, having successfully commercialized CAPLYTA® and continued its market growth post-acquisition by J&J, which is expected to significantly support Seaport's mission.
- Strategic Collaboration Outlook: Dr. Mates expressed great interest in Seaport's programs and looks forward to collaborating closely with founder Daphne Zohar and other team members to drive the company's continued growth and develop life-changing treatments for patients.
- Innovative Drug Development: Seaport Therapeutics focuses on developing new medicines for depression, anxiety, and other neuropsychiatric disorders, and Dr. Mates' addition is anticipated to enhance the company's R&D capabilities, helping it stand out in a competitive market.
See More
Benitec Biopharma Showcases BB-301 Clinical Results at MDA Conference
- Clinical Research Progress: Benitec showcased key clinical results for BB-301 at the 2026 MDA Conference, demonstrating significant and durable improvements in swallowing function and dysphagia symptom burden, potentially transforming the treatment landscape for OPMD patients.
- Patient Impact: With approximately 97% of OPMD patients suffering from severe dysphagia, BB-301's treatment could significantly enhance patients' quality of life by replacing the mutated PABPN1 gene with a functional protein, thereby reducing the risk of complications.
- Industry Forum Event: The Industry Forum Breakfast is scheduled for March 10, 2026, where Benitec's CEO Jerel A. Banks will present detailed clinical data on BB-301, attracting numerous industry experts and further enhancing the company's influence in the biotechnology sector.
- Regulatory Recognition: BB-301 has received Orphan Drug Designation from the EMA and both Orphan Drug and Fast Track Designations from the FDA, indicating its potential in treating rare diseases and possibly bringing future market opportunities and investor confidence to Benitec.
See More
Benitec Reports Q2 Earnings Miss with Strategic Upgrade
- Earnings Report Disappointment: Benitec's Q2 GAAP EPS of -$0.26 missed expectations by $0.03, resulting in a net loss of $11.8 million, indicating ongoing financial strain on the company.
- Market Reaction: Despite the earnings miss, early data from Benitec's BB-301 project and a cash infusion provide support for its future development, leading to a bullish outlook from the market.
- Rating Adjustment: Seeking Alpha's Quant Rating has classified Benitec's stock as bullish, reflecting analysts' confidence in its potential growth despite current financial challenges.
- Historical Financial Data: Historical financial data for Benitec shows that, despite facing challenges, the company is striving to improve its operational efficiency and market positioning to better compete in the future.
See More
Significant Progress in BB-301 Clinical Trials
- Responder Analysis: All four patients in Cohort 1 of the BB-301 study were formal responders at the 12-month follow-up, demonstrating durable responses to treatment, indicating the therapy's effectiveness in addressing Oculopharyngeal Muscular Dystrophy-related dysphagia.
- Long-term Efficacy Observation: Patient 1 showed continued disease-modifying effects at the 24-month follow-up, with significant improvements in post-swallow residue and total dysphagic symptom burden, suggesting BB-301 may provide long-term therapeutic benefits.
- FDA Meeting Scheduled: The company plans to engage with the FDA in mid-2026 to formalize the pivotal study design for BB-301, which will lay the groundwork for the successful progression of subsequent clinical trials.
- Financial Status Update: As of December 31, 2025, the company reported $189 million in cash and cash equivalents, and despite an operating loss of $13.8 million, R&D expenses remained consistent with the previous year, reflecting the company's commitment to advancing clinical development.
See More
Benitec Biopharma Announces Financial Results for Q2 2026 and Offers Operational Update
Financial Results: Benitec Biopharma has released its financial results for the second quarter of 2026, detailing its performance and financial health during this period.
Operational Update: The company has provided an operational update, highlighting key developments and progress in its ongoing projects and initiatives.
See More
Benitec Biopharma Reports Q2 EPS of USD -0.26
Company Overview: Benitec Biopharma is a biotechnology company focused on developing innovative therapies using its proprietary gene-silencing technology.
Financial Performance: The company reported a Q2 EPS of USD -0.26, indicating a loss per share for the quarter.
See More
